Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS1003 plus lenvatinib versus placebo plus lenvatinib in first-line advanced hepatocellular carcinoma
2019-003337-41Phase 3Completed
- Sponsor
- CStone Pharmaceuticals
- Start
- Dec 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing CS1003 + lenvatinib with Placebo + lenvatinib (2 arms). Primary endpoint: Progression-free survival. Started Dec 2019; status: completed.
02
Drugs
nofazinlimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2019-003337-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003337-41.